Herath Manoja P, Beckett Jeffrey M, Hills Andrew P, Byrne Nuala M, Ahuja Kiran D K
School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS 7248, Australia.
J Clin Med. 2021 Feb 18;10(4):835. doi: 10.3390/jcm10040835.
Exposure to untreated gestational diabetes mellitus (GDM) in utero increases the risk of obesity and type 2 diabetes in adulthood, and increased adiposity in GDM-exposed infants is suggested as a plausible mediator of this increased risk of later-life metabolic disorders. Evidence is equivocal regarding the impact of good glycaemic control in GDM mothers on infant adiposity at birth. We systematically reviewed studies reporting fat mass (FM), percent fat mass (%FM) and skinfold thicknesses (SFT) at birth in infants of mothers with GDM controlled with therapeutic interventions (IGDMtr). While treating GDM lowered FM in newborns compared to no treatment, there was no difference in FM and SFT according to the type of treatment (insulin, metformin, glyburide). IGDMtr had higher overall adiposity (mean difference, 95% confidence interval) measured with FM (68.46 g, 29.91 to 107.01) and %FM (1.98%, 0.54 to 3.42) but similar subcutaneous adiposity measured with SFT, compared to infants exposed to normal glucose tolerance (INGT). This suggests that IGDMtr may be characterised by excess fat accrual in internal adipose tissue. Given that intra-abdominal adiposity is a major risk factor for metabolic disorders, future studies should distinguish adipose tissue distribution of IGDMtr and INGT.
子宫内暴露于未经治疗的妊娠期糖尿病(GDM)会增加成年后患肥胖症和2型糖尿病的风险,而暴露于GDM的婴儿体内脂肪增加被认为是晚年代谢紊乱风险增加的一个合理中介因素。关于GDM母亲良好的血糖控制对婴儿出生时肥胖的影响,证据并不明确。我们系统回顾了有关接受治疗性干预控制的GDM母亲(IGDMtr)所生婴儿出生时脂肪量(FM)、脂肪量百分比(%FM)和皮褶厚度(SFT)的研究报告。与未治疗相比,治疗GDM可降低新生儿的FM,但根据治疗类型(胰岛素、二甲双胍、格列本脲),FM和SFT并无差异。与暴露于正常糖耐量(INGT)的婴儿相比,IGDMtr通过FM(68.46克,29.91至107.01)和%FM(1.98%,0.54至3.42)测量的总体肥胖程度更高,但通过SFT测量的皮下肥胖程度相似。这表明IGDMtr的特征可能是内脏脂肪组织中脂肪积累过多。鉴于腹内肥胖是代谢紊乱的主要危险因素,未来的研究应区分IGDMtr和INGT的脂肪组织分布情况。